Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is an Angiotensin II receptor blocker (ARB) presented as oral tablets for oral use. It is prescribed to manage hypertension and to slow the progression of diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including distribution across the EU, Asia and the Americas, with support for import documentation and post‑market surveillance.

Irbesartan is an angiotensin II receptor blocker used to treat conditions related to the renin‑angiotensin system. - Hypertension: lowers blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate pain often resolves with continued therapy. - Fatigue: general tiredness without a clear cause. - Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat requiring urgent medical attention. - Hyperkalemia: elevated blood potassium that may cause cardiac rhythm disturbances. - Acute renal impairment: sudden decline in kidney function, especially in patients with pre‑existing renal disease.

Irbesartan should be used with careful clinical monitoring. - Blood pressure monitoring: check regularly to ensure therapeutic effect. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Serum potassium monitoring: especially when combined with potassium‑sparing agents. - Hepatic impairment caution: dose adjustment may be needed in patients with liver disease. - Pregnancy warning: avoid use during pregnancy as safety is not established. - Store below 25°C: keep in the original pack, protect from moisture.

Irbesartan may interact with several medicines. Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase renal risk. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: may blunt antihypertensive effect and affect kidney.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may require dose adjustment of irbesartan. - Lithium: increased lithium levels, monitor serum concentration. - Cyclosporine or tacrolimus: may raise irbesartan plasma concentrations.